Nations jockey to see who gets coronavirus vaccine first | TheHill
Companies, agencies, institutions, etc
IG
MLB
AP
Food and Drug Administration
The Wall Street Journal
Sanofi
Bloomberg News
Notre Dame
World Health Organization
Trump
WHO
Oxford University
that.”The White House
State Department
State Dept
Moderna
Inovio
Pfizer
BioNTech
the Journal of the American Medical Association
the Center for Global Development
NW Suite 900 Washington DC
Capitol Hill Publishing Corp.
News Communications
People
Scott Gottlieb
John TrumpChina's
Romney
Paul Hudson
Bloomberg
Emmanuel MacronEmmanuel
Jean-Michel MacronNeeded
Merkel
Adrian Hill
Mike PompeoMichael
Richard PompeoChina's
Sharon Castillo
Thomas Bollyky
Lawrence Gostin
Margaret Hamburg
Prashant Yadav
Groups
French
COVID-19
Democrats
Pompeo Democrats
Israeli
German
Physical locations
Europe
Hudson
Places
the White House
Locations
U.S.
China
America
France
the United Kingdom
U.K.
Pfizer
the United States
Inc.
Events
No matching tags
Summary
Scott Gottlieb, President TrumpDonald John TrumpChina's top medical adviser warns country is vulnerable to second wave of COVID-19 infections Romney denounces multiple IG firings as 'threat to accountable democracy' MLB predicts billions in losses upon return to baseball season: AP MORE’s former Food and Drug Administration commissioner, wrote an op-ed in The Wall Street Journal last month titled “America Needs to Win the Coronavirus Vaccine Race,” arguing that “the U.S. can’t rely on vaccines from China or even Europe being available in America quickly.”“It's not politically correct to say it, but it's inevitable that the first country that's able to mass inoculate the population’s going to probably have more of an ability to experience an economic recovery than other nations that will be further behind in that race,” Gottlieb said Wednesday during a forum hosted by the Duke Margolis Center for Health Policy. Yadav said one way to deal with allocation of the vaccine between countries would be for the U.S. to use the first 100 million doses of a U.S.-made vaccine to inoculate vulnerable people like the elderly and health care workers, and then make the next batch of vaccines available to other countries.
As said here by Peter Sullivan